Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSK | P43235 | 8/20 | 0.45 |
| ▸ | CTSS | P25774 | 3/20 | 0.43 |
| ▸ | ITGB3 | P05106 | 4/20 | 0.40 |
| ▸ | ITGA2B | P08514 | 4/20 | 0.40 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | CAPN1 | P07384 | 1/20 | 0.38 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1161276 | 1.00 | CTSK (0.45) | CTSKCTSSITGB3ITGA2BCYP2D6 | |
| SCHEMBL4058903 | 0.89 | CTSK (0.51) | CTSKCTSSITGB3ITGA2BCYP2D6 | |
| SCHEMBL3719232 | 0.89 | CTSK (0.51) | CTSKCTSSITGB3ITGA2BCYP2D6 | |
| SCHEMBL8176917 | 0.89 | CTSK (0.51) | CTSKCTSSITGB3ITGA2BCYP2D6 | |
| SCHEMBL7065541 | 0.86 | CTSK (0.46) | CTSKCTSSITGB3ITGA2BCYP1A2 | |
| SCHEMBL2222627 | 0.86 | CTSK (0.46) | CTSKCTSSITGB3ITGA2BCYP1A2 | |
| SCHEMBL9103059 | 0.85 | EPHX1 (0.41) | ITGB3ITGA2BCYP1A2CYP2C19EPHX1 | |
| SCHEMBL13183147 | 0.83 | NOD1 (0.47) | CTSKCTSSITGB3ITGA2B | |
| SCHEMBL7700116 | 0.82 | CYP2D6 (0.39) | CTSKCTSSITGB3ITGA2BCYP2D6 | |
| SCHEMBL7404539 | 0.82 | ACHE (0.46) | EPHX1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-104593173-A | Detergent for grapes | YANTAI SHUNLONG CHEMICAL TECHNOLOGY CO LTD | 2015-05-06 | — | — | CN | disclosed |
| US-7618968-B2 | Aryl triazines as LPAAT-β inhibitors and uses thereof | CELL THERAPEUTICS, INC. (US) | 2009-11-17 | — | — | US | disclosed |
| US-20080064700-A1 | Aryl triazines as LPAAT-beta inhibitors and uses thereof | CELL THERAPEUTICS, INC. (US) | 2008-03-13 | — | — | US | disclosed |
| US-7291616-B2 | Aryl triazines as LPAAT-β inhibitors and uses thereof | CELL THERAPEUTICS, INC. (US) | 2007-11-06 | — | — | US | disclosed |
| US-20030153570-A1 | Aryl triazines as LPAAT-SS inhibitors and uses thereof | CELL THERAPEUTICS, INC. (US) | 2003-08-14 | — | — | US | disclosed |
| WO-2003037346-A1 | 6-PHENYL-N-PHENYL-(1,3,5) -TRIAZINE-2,4-DIAMINE DERIVATIVES AND RELATED COMPOUNDS WITH LYSOPHPHOSPHATIDIC ACID ACYLTRANSFERASE BETA (LPAAT-BETA) INHIBITORY ACTIVITY FOR USE IN THE TREATMENT OF CANCER | CELL THERAPEUTICS, INC. (US) | 2003-05-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030153570-A1 | Aryl triazines as LPAAT-SS inhibitors and uses thereof | LPCAT3, LPCAT1, PLAAT2 | CTSK 2135/4885CTSS 983/4885ITGB3 4263/4885 |
| US-20080064700-A1 | Aryl triazines as LPAAT-beta inhibitors and uses thereof | LPCAT3, LPCAT1, PLAAT2 | CTSK 2195/4885CTSS 2353/4885ITGB3 2489/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.